For the millions of people living with chronic obstructive pulmonary disease, the past two years have delivered something genuinely rare in respiratory medicine: a fundamental shift in how the disease is treated. The FDA’s approval of dupilumab as the first-ever biologic for COPD in March 2026, combined with the arrival of ensifentrine and mepolizumab, means that patients who once had nowhere to turn after triple inhaler therapy now have real options backed by large clinical trials. In the BOREAS trial of 939 adults, dupilumab reduced moderate-to-severe exacerbations by 30 percent over 52 weeks, while the confirmatory NOTUS trial of 935 patients showed an even stronger 34 percent reduction. These are not incremental gains. For a disease that kills more than three million people worldwide each year, they represent the most significant therapeutic advances in over two decades.
This matters for readers of a brain health site more than you might expect. COPD exacerbations cause oxygen deprivation, systemic inflammation, and hospitalizations that dramatically accelerate cognitive decline, particularly in older adults already at risk for dementia. Research has consistently linked poorly controlled COPD with faster progression of vascular dementia and Alzheimer’s disease. Fewer exacerbations means more stable oxygenation, less neuroinflammation, and better long-term brain health outcomes for patients managing both conditions. This article covers the specific drug breakthroughs reshaping COPD care, including how each works, what the clinical trial data actually shows, the costs and access barriers patients face, and what the 2025 GOLD guidelines now recommend. We will also look at the pipeline of biologics still in development and what caregivers should know when advocating for a loved one with both COPD and cognitive impairment.
Table of Contents
- What Drug Combinations Are Changing COPD Treatment Outcomes?
- How Biologics Are Redefining Severe COPD Management
- Triple Therapy and the Mortality Evidence from the ETHOS Trial
- Comparing Costs and Access Barriers Across New COPD Therapies
- What the 2025 GOLD Guidelines Mean for Patients with COPD and Cognitive Decline
- Inhaler Technique and Cognitive Impairment — A Practical Challenge
- What Comes Next in the COPD Treatment Pipeline
- Conclusion
- Frequently Asked Questions
What Drug Combinations Are Changing COPD Treatment Outcomes?
The short answer is that COPD treatment has moved from a one-size-fits-all inhaler approach to a layered strategy that now includes biologics targeting specific inflammatory pathways. Triple therapy, which combines an inhaled corticosteroid, a long-acting beta-agonist, and a long-acting muscarinic antagonist (ICS/LABA/LAMA), remains the foundation. But for patients whose disease remains uncontrolled on triple therapy, dupilumab can now be added as a fourth layer. The 2025 GOLD guidelines specifically recommend adding dupilumab to triple therapy for patients with blood eosinophil counts of 300 cells per microliter or higher and symptoms of chronic bronchitis. This is a significant departure from previous guidelines, which essentially left these patients without further escalation options. Dupilumab works by blocking interleukin-4 and interleukin-13, two signaling molecules that drive type 2 inflammation.
This is the same mechanism that made the drug successful in severe asthma and atopic dermatitis, but its application to COPD required proving efficacy in a patient population that is older, sicker, and has more structural lung damage. The BOREAS and NOTUS trials did exactly that. In both studies, patients were already on maximal inhaler therapy, and dupilumab still delivered meaningful exacerbation reductions with an adverse event profile nearly identical to placebo: 67 percent of dupilumab patients experienced side effects compared to 66 percent on placebo, with the most common being diarrhea, back pain, and headache. Meanwhile, ensifentrine, approved in June 2024 under the brand name Ohtuvayre, introduced an entirely different approach. As the first dual PDE3/PDE4 inhibitor, it combines bronchodilator and anti-inflammatory effects in a single inhaled molecule, something no previous COPD medication had achieved. Pooled data from the ENHANCE-1 and ENHANCE-2 trials showed a 40 percent reduction in moderate-to-severe exacerbations at 24 weeks, with lung function improvements of 87 mL and 94 mL in FEV1 respectively. The number needed to treat was just 6.25 to prevent one annual exacerbation, a figure that clinicians consider quite favorable.
How Biologics Are Redefining Severe COPD Management
The emergence of biologics for COPD represents a philosophical shift in how pulmonologists think about the disease. For decades, COPD was treated primarily as an airflow obstruction problem. Bronchodilators opened the airways, steroids dampened inflammation broadly, and that was essentially the toolkit. Biologics treat COPD as an immunologically heterogeneous condition where specific inflammatory subtypes can be identified through biomarkers like blood eosinophil counts and targeted with precision therapies. Mepolizumab, marketed as Nucala, became the second biologic approved for COPD when the FDA cleared it in May 2025 as add-on maintenance therapy for adults with inadequately controlled disease and an eosinophilic phenotype. The MATINEE trial enrolled 804 patients with eosinophil counts of 300 cells per microliter or higher who were already on triple therapy.
The exacerbation rate dropped from 1.01 per year on placebo to 0.80 per year on mepolizumab, a rate ratio of 0.79 that reached statistical significance. While the absolute reduction may look modest on paper, for a patient who has been hospitalized repeatedly for exacerbations, even one fewer episode per year can mean the difference between maintaining independence and requiring full-time care. However, biologics are not appropriate for every COPD patient, and this is a critical distinction. These drugs work specifically in patients with eosinophilic inflammation, which accounts for roughly 20 to 40 percent of the COPD population. A patient with a predominantly neutrophilic inflammatory profile, which is common in current or recent smokers, is unlikely to benefit from dupilumab or mepolizumab. If a clinician prescribes a biologic without first confirming elevated eosinophils through a simple blood test, the expense and effort will almost certainly be wasted. This is particularly relevant for dementia caregivers advocating for a loved one, as cognitive impairment can make it harder for patients to communicate whether they feel improvement on a new medication.
Triple Therapy and the Mortality Evidence from the ETHOS Trial
One of the most striking findings in recent COPD research came not from a biologic but from a specific triple therapy inhaler. The ETHOS trial evaluated Breztri Aerosphere, a combination of budesonide, glycopyrrolate, and formoterol, and found a 46 percent reduction in all-cause mortality compared to dual bronchodilator therapy at the higher inhaled corticosteroid dose. The hazard ratio was 0.51, with a P value of 0.0035. That is a survival benefit rarely seen in COPD trials, a disease where demonstrating mortality reduction has been notoriously difficult. The trial also showed a 24 percent reduction in exacerbations compared to dual bronchodilator therapy and a 13 percent reduction compared to an ICS/LABA combination without the long-acting muscarinic antagonist component.
These results have been influential enough that AstraZeneca initiated the Phase III THARROS trial in 2024 to further evaluate Breztri’s impact on cardiopulmonary outcomes. If confirmed, this would solidify the case that the specific combination and dosing in Breztri provides benefits beyond what other triple therapy inhalers have demonstrated. For patients with both COPD and dementia risk factors, the mortality data is especially relevant. Hospitalizations for COPD exacerbations are strongly associated with post-hospital cognitive decline, and each severe exacerbation carries a risk of delirium that can permanently worsen baseline cognitive function. A therapy that reduces both exacerbations and mortality addresses the cardiovascular and cerebrovascular burden that links COPD to dementia progression. Caregivers and geriatricians should consider these broader cognitive implications when making treatment decisions, not just the pulmonary endpoints.
Comparing Costs and Access Barriers Across New COPD Therapies
The clinical promise of these new treatments collides with a difficult reality: they are expensive, and access is uneven. Ensifentrine carries a list price of approximately $2,950 per month, or $35,400 per year. The Institute for Clinical and Economic Review issued an access and affordability alert, concluding that a price between $7,500 and $12,700 per year would be needed to meet standard cost-effectiveness thresholds. That gap between the actual price and the recommended price is substantial and raises serious questions about long-term sustainability, particularly for Medicare patients who make up a large share of the COPD population. Dupilumab, already on the market for other conditions, carries a similarly high price point that is well established from its use in asthma and eczema. The addition of a COPD indication expands the eligible population significantly, but insurance coverage battles remain common. Many patients report prior authorization requirements, step therapy mandates requiring documented failure on cheaper medications, and appeals processes that can take weeks or months.
For a patient with both COPD and cognitive impairment, navigating these bureaucratic obstacles without a dedicated caregiver or advocate can be functionally impossible. The tradeoff is clearest when comparing ensifentrine to dupilumab. Ensifentrine is an inhaled medication that acts as both a bronchodilator and anti-inflammatory, making it potentially useful across a broader COPD population regardless of eosinophil status. Dupilumab is an injectable biologic that targets a specific inflammatory pathway and requires biomarker confirmation. For a patient with high eosinophils on maximal therapy who continues to exacerbate, dupilumab offers a 30 to 34 percent reduction in exacerbations. For a patient with persistent dyspnea despite standard treatment, ensifentrine offers a 40 percent exacerbation reduction at 24 weeks plus measurable lung function improvement. Neither is clearly superior to the other because they serve different patient profiles and can potentially be used together, though combination data is still limited.
What the 2025 GOLD Guidelines Mean for Patients with COPD and Cognitive Decline
The 2025 GOLD guidelines represent the most significant update to COPD management recommendations in years. Triple therapy with ICS/LABA/LAMA remains the gold standard for patients prone to exacerbations, but the guidelines now formally incorporate biologics into the treatment algorithm. Specifically, they recommend adding dupilumab to triple therapy for patients who continue to exacerbate despite optimal inhaler use, provided eosinophils are 300 cells per microliter or higher and chronic bronchitis symptoms are present. Ensifentrine is also included as a potential add-on for patients with dyspnea that persists despite standard treatment. This matters for dementia care because COPD guidelines have historically focused on lung function metrics that may not capture the full impact of the disease on older adults with cognitive impairment. A patient with moderate dementia may not be able to perform spirometry reliably, making FEV1 an unreliable metric for treatment decisions.
Exacerbation frequency and hospitalization rates become more meaningful endpoints in this population, and these are exactly the outcomes where the new biologics show their strongest effects. Caregivers should understand that the GOLD guidelines now support escalation beyond inhalers for appropriate patients and should feel empowered to ask pulmonologists about biologic eligibility. A word of caution: the guidelines also note that several additional biologics remain under investigation, including benralizumab, which targets the IL-5 receptor, and agents targeting the IL-33 and TSLP pathways such as astegolimab, itepekimab, and tezepelumab. These are not yet approved for COPD, and patients should be wary of clinics promoting unapproved treatments. The evidence base for dupilumab and mepolizumab is solid. The evidence for these pipeline drugs is still being built through ongoing trials.
Inhaler Technique and Cognitive Impairment — A Practical Challenge
Even the best COPD medications fail when they are not used correctly, and this is where the intersection of COPD and dementia creates a uniquely difficult problem. Studies consistently show that 50 to 80 percent of COPD patients use their inhalers incorrectly, and cognitive impairment makes proper technique even harder to maintain. A patient who was able to coordinate a metered-dose inhaler at the time of diagnosis may lose that ability as dementia progresses, rendering their triple therapy ineffective regardless of which drugs it contains.
This practical reality is one reason why the shift toward injectable biologics like dupilumab and mepolizumab may be especially valuable for COPD patients with cognitive decline. These medications are administered by injection, typically every two weeks for dupilumab, and can be given by a caregiver or healthcare professional. They bypass the coordination and technique requirements that make inhaled medications unreliable in cognitively impaired patients. For a caregiver managing a loved one with both conditions, asking the pulmonologist about injectable options is a conversation worth having, particularly if there are signs that inhaler technique has deteriorated.
What Comes Next in the COPD Treatment Pipeline
The current wave of approvals is likely just the beginning. The COPD treatment pipeline is more active than it has been in decades, with multiple biologics and novel small molecules in late-stage trials. Benralizumab, already approved for severe eosinophilic asthma, is being studied in COPD patients with similar inflammatory profiles. Agents targeting upstream inflammatory mediators like IL-33 and thymic stromal lymphopoietin represent an effort to intervene even earlier in the inflammatory cascade that drives exacerbations.
The ongoing THARROS trial evaluating Breztri’s cardiopulmonary outcomes could further reshape treatment algorithms if it confirms the mortality benefits seen in ETHOS. For patients and caregivers, the practical message is that COPD treatment is no longer static. A management plan that was optimal two years ago may now be outdated. Regular reassessment with a pulmonologist, including eosinophil testing and a frank discussion about exacerbation frequency and treatment goals, should be part of routine care. This is doubly important for patients with comorbid cognitive impairment, where every prevented hospitalization and every avoided exacerbation protects not just the lungs but the brain.
Conclusion
The treatment landscape for COPD has changed more in the past two years than in the previous two decades. The arrival of dupilumab and mepolizumab as the first biologics approved for COPD, the novel mechanism of ensifentrine, and the compelling mortality data from the ETHOS trial with Breztri have collectively given clinicians tools that would have been unimaginable a few years ago. For patients with eosinophilic COPD who continue to exacerbate on triple therapy, biologics now offer a proven path to fewer flare-ups, fewer hospitalizations, and more stable respiratory function.
For those caring for someone with both COPD and dementia or cognitive decline, these advances carry particular significance. Every exacerbation prevented is a hospitalization avoided, a bout of delirium sidestepped, and a period of dangerous oxygen deprivation that will not happen. Talk with your loved one’s pulmonologist about eosinophil testing, biologic eligibility, and whether their current treatment plan reflects the 2025 GOLD guidelines. The options are better than they have ever been, but only if patients and caregivers know to ask for them.
Frequently Asked Questions
What is the first biologic approved for COPD?
Dupilumab, marketed as Dupixent, was approved by the FDA in March 2026 as the first biologic treatment for COPD. It is indicated for patients with uncontrolled COPD and an eosinophilic phenotype, and it works by inhibiting IL-4 and IL-13 signaling pathways that drive type 2 inflammation.
How much do the new COPD biologic treatments cost?
These treatments are expensive. Ensifentrine (Ohtuvayre) costs approximately $2,950 per month or $35,400 per year, though the Institute for Clinical and Economic Review has recommended a price of $7,500 to $12,700 per year to meet cost-effectiveness thresholds. Dupilumab and mepolizumab carry similarly high price points. Insurance coverage varies and often requires prior authorization.
Can COPD exacerbations worsen dementia symptoms?
Yes. COPD exacerbations cause oxygen deprivation and systemic inflammation, both of which are associated with accelerated cognitive decline. Hospitalizations for severe exacerbations also carry a significant risk of delirium, which can cause lasting worsening of baseline cognitive function in older adults.
Who is eligible for biologic COPD treatment?
Biologics like dupilumab and mepolizumab are specifically indicated for patients with eosinophilic COPD, identified by blood eosinophil counts of 300 cells per microliter or higher. The 2025 GOLD guidelines recommend adding dupilumab to triple therapy for patients who continue to experience exacerbations despite optimal inhaler use and who have chronic bronchitis symptoms.
What is ensifentrine and how is it different from biologics?
Ensifentrine, brand name Ohtuvayre, is an inhaled dual PDE3/PDE4 inhibitor approved in June 2024. Unlike biologics, which are injectable and target specific immune pathways, ensifentrine combines bronchodilator and anti-inflammatory effects in a single inhaled molecule. It was the first inhaled product with a novel mechanism of action for COPD maintenance in over 20 years.
Did any COPD treatment show a reduction in mortality?
Yes. The ETHOS trial found that Breztri Aerosphere, a triple therapy combining budesonide, glycopyrrolate, and formoterol, showed a 46 percent reduction in all-cause mortality compared to dual bronchodilator therapy at the higher ICS dose, with a hazard ratio of 0.51 and a P value of 0.0035.
